Back to top
more

Biogen (BIIB)

(Delayed Data from NSDQ)

$173.04 USD

173.04
1,581,725

-0.88 (-0.51%)

Updated Nov 8, 2024 04:00 PM ET

After-Market: $173.02 -0.02 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Lilly Gets FDA Approval for Eczema Drug Ebglyss

by Zacks Equity Research

The FDA approves Lilly's Ebglyss based on data from ADvocate 1, ADvocate 2 and ADhere studies.

Here's Why Biogen Inc. (BIIB) is a Strong Value Stock

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Ionis Stock Drops 12% on Pricing of $500M Common Stock Offering

by Zacks Equity Research

IONS' shares fell after announcing the pricing of its secondary issue of shares, which were at a 12% discount to the previous closing price.

Amgen (AMGN) Up 5.8% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Biogen's Phase II/III SMA Study for Higher Spinraza Dose Meets Goals

by Zacks Equity Research

BIIB's pivotal mid to late-stage study evaluating a higher dosing regimen for Spinraza to treat SMA in infants meets the primary and secondary goals.

Denali Plans to File for Accelerated Approval of Hunter Syndrome Drug

by Zacks Equity Research

DNLI's recent meeting with the FDA was successful and provides the path to file for accelerated approval of tividenofusp alfa for the treatment of MPS II and its subsequent conversion to full approval.

ATHA Stock Tanks as Alzheimer's Study Fails to Meet Primary Goal

by Zacks Equity Research

Athira's phase II/III LIFT-AD study on fosgonimeton for treating mild-to-moderate Alzheimer's disease fails to meet primary and secondary endpoints.

Kinjel Shah headshot

Biogen Stock Declines 20.9% Year to Date: Time to Sell?

by Kinjel Shah

BIIB's reasonable valuation, an improving pipeline and better sales prospects of new drugs are good enough reasons to stay invested for now.

Why Biogen Inc. (BIIB) is a Top Value Stock for the Long-Term

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Do Options Traders Know Something About Biogen (BIIB) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to Biogen (BIIB) stock based on the movements in the options market lately.

Will Ionis' (IONS) Wholly-Owned Drugs Drive Future Growth?

by Zacks Equity Research

Ionis (IONS) enjoys a diverse revenue stream, including numerous sources of collaborative and R&D revenues. These funds enable it to invest in the development of its wholly-owned pipeline.

Kinjel Shah headshot

Is Eli Lilly (LLY) a Buy Post Stellar Q2 Earnings & Raised View?

by Kinjel Shah

Eli Lilly (LLY) is a great stock to have in one's portfolio currently based on its strong overall financial performance and robust drug pipeline.

The Zacks Analyst Blog Highlights Eli Lilly, Pfizer, AbbVie and Biogen

by Zacks Equity Research

Eli Lilly, Pfizer, AbbVie and Biogen are part of the Zacks top Analyst Blog.

Kinjel Shah headshot

3 Big Drug Stocks to Watch on Raised 2024 Earnings & Sales View

by Kinjel Shah

Here we discuss three drugmakers, Eli Lilly and Company (LLY), Pfizer (PFE) and AbbVie (ABBV), following their increase in sales and earnings guidance for 2024.

Eli Lilly (LLY) Q2 Earnings Top, Mounjaro, Zepbound Drive View

by Zacks Equity Research

Eli Lilly (LLY) beats second-quarter estimates for earnings and sales. It raises its guidance for 2024 on strong demand for Mounjaro and Zepbound.

Kinjel Shah headshot

Should You Buy, Sell or Hold Lilly (LLY) Ahead of Q2 Earnings?

by Kinjel Shah

Investor focus is likely to be on the sales numbers of Lilly's (LLY) tirzepatide medicines Mounjaro and Zepbound.

Ionis (IONS) Q2 Earnings and Revenues Beat, Stock Rises

by Zacks Equity Research

Ionis (IONS) reports better-than-expected top and bottom-line numbers for the second quarter of 2024.

Here's Why Biogen Inc. (BIIB) is a Strong Value Stock

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Ekta Bagri headshot

Biotech Stock Roundup: BMY, GSK, BIIB's Q2 Results, VTVT Down on Setback

by Ekta Bagri

Bristol Myers (BMY) and Biogen (BIIB) are in the spotlight following earnings results and regulatory updates, respectively.

Biogen (BIIB) Q2 Earnings & Sales Beat, 2024 Guidance Raised

by Zacks Equity Research

Biogen (BIIB) beats second-quarter estimates for both earnings and sales. It raises EPS guidance and revenue growth expectations for 2024.

Sage Therapeutics (SAGE) Q2 Loss Wider Than Expected, Sales Rise

by Zacks Equity Research

Sage Therapeutics (SAGE) incurs a wider-than-expected second-quarter 2024 loss. Collaboration revenues from Zurzuvae drive year-over-year revenue growth.

Jobless Claims Tick in Higher

by Zacks Equity Research

Jobless Claims Tick in Higher.

Mark Vickery headshot

Jobless Claims, Productivity Higher; TM, WEN, CROX Report

by Mark Vickery

Initial Jobless Claims came in at their highest levels in almost a year, to 249K -- well above the 235K anticipated.

Biogen (BIIB) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

While the top- and bottom-line numbers for Biogen (BIIB) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Biogen Inc. (BIIB) Q2 Earnings and Revenues Top Estimates

by Zacks Equity Research

Biogen (BIIB) delivered earnings and revenue surprises of 32% and 3.54%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?